Loading stock data…
$3.01-0.03 (-0.99%)
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland.
Addex Therapeutics Ltd in the Healthcare sector is trading at $3.01 with a market capitalization of $7M. The stock is currently near its 52-week low of $2.56, remaining 50.9% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $248↓ | $29,724 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$479,827↑ | -$779,263↓ | -$696,175↑ | -$732,898↓ | -$606,262 |
| Net Income | -$1.71M↑ | -$1.84M↓ | -$1.58M↑ | -$1.84M↓ | -$1.47M |
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs includ...